GlassScriptPhysician profile
Shani T Lampley
NPI 1568723955
$14,654.26
in general payments reported to CMS, 2019-2025
58 companies · $1,569 in 2025
The $1,569 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,288 · 2020: $2,163 · 2021: $3,111 · 2022: $3,039 · 2023: $1,716 · 2024: $1,767 · 2025: $1,569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,048 · Education: $4.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,047.82 |
| Education | $4.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,230.07 | 2019-2025 | |
| Novo Nordisk INC | $1,850.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,333.62 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $1,037.14 | 2021-2025 | |
| Amgen INC. | $828.92 | 2019-2025 | Repatha, Otezla, Aimovig |
| Astrazeneca Pharmaceuticals LP | $742.95 | 2019-2025 | Airsupra, Farxiga |
| Amarin Pharma, INC. | $527.60 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $431.39 | 2019-2025 | Xifaxan |
| Allergan, INC. | $422.38 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $420.99 | 2019-2024 | Trintellix |
| Pfizer INC. | $381.04 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $378.28 | 2019-2023 | Livalo |
| Glaxosmithkline, LLC. | $347.59 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Eisai INC. | $313.86 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $299.88 | 2020-2024 | Jardiance |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shani Lampley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.